Page 5 - Ndpoint Threat Detection And Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ndpoint threat detection and response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ndpoint Threat Detection And Response Today - Breaking & Trending Today

Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma

The central independent review concluded that the NIPU study did not meet the primary endpoint of progression-free survival . However, a statistically significant improvement in PFS for. | June 7, 2023 ....

Bristol Myers Squibbs , Bristol Myers Squibb , Halle University , International Agency For Research On Cancer Globocan , Professor At Oslo University Hospital , Oslo University Hospital , Principal Investigator , Oslo University , Carlos De Sousa , Chief Executive Officer , International Agency , Human Leukocyte Antigen , Ultimovacs Asa Stock Exchange , Press Release , Fs Ulti No0010851603 ,

Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

The application is supported by the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival compared to standard regimens

CARTITUDE-4 is the. | June 6, 2023 ....

United States , New Jersey , Ying Huang , Hemophagocytic Lymphohistiocytosis , European Hematology Association , Janssen Biotech Inc , Community Register Of Orphan Medicinal Products , Exchange Commission On , American Cancer Society , European Commission , Medicinal Devices Agency , Data Monitoring Committee , American Society Of Clinical Oncology , Drug Administration , Japan Ministry Of Health , European Commission For The Treatment Of Patients , Legend Biotech Corporation , Legend Biotech , Biologics License Application , Chief Executive Officer , Clinical Oncology , Annual Meeting , New England Journal , Hematology Association , Hybrid Congress , Independent Data Monitoring Committee ,

Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile. | June 5, 2023 ....

Peter Fernandes , Brian Ritchie , Bellerophon Therapeutics Inc , Exchange Commission , Globenewswire Inc , Interstitial Lung Disease , Walk Distance , Respiratory Questionnaire , Clinical Worsening , Clinical Deterioration , Clinical Improvement , Chief Executive , Private Securities Litigation Reform Act , Annual Report , Sci Advisors , Bellerophon Therapeutics , Nc Stock Exchange , Press Release , Afety Blph Us0787713009 ,

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

- Investigator-led Phase IIa study met its primary endpoint of disease control rate at 12 weeks -

BERGEN, Norway, June 5, 2023 - BerGenBio ASA , a clinical-stage biopharmaceutical company. | June 5, 2023 ....

United States , United Kingdom , Matthew Krebs , Martin Olin , Matt Krebs , Jan Lilleby , Oslo Stock Exchange , American Society Of Clinical Oncology , Research Excellence Framework , Russell Group , University Of Leicester , University Of Manchester , British Lung Foundation , Clinical Oncology , Annual Meeting , Mesothelioma Stratified Therapy , Lung Foundation , Chief Executive Officer , Stock Exchange , Times Higher Education , Academic Ranking , World Universities , Times Higher Education Impact Rankings , Graduate Market , Bergenbio Asa Stock Exchange , Press Release ,

Novartis Says Kisqali Significantly Lowered the Risk of Cancer Recurrence

By Giulia Petroni

Novartis said that primary endpoint data from a Phase 3 trial showed that ribociclib drug treatment Kisqali significantly reduced the risk of cancer recurrence across a. | June 2, 2023 ....

Giulia Petroni , Dow Jones , Novartis Ag Stock Exchange , Press Release , Cross Novn Ch0012005267 ,